ATE93138T1 - Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie. - Google Patents

Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.

Info

Publication number
ATE93138T1
ATE93138T1 AT91904163T AT91904163T ATE93138T1 AT E93138 T1 ATE93138 T1 AT E93138T1 AT 91904163 T AT91904163 T AT 91904163T AT 91904163 T AT91904163 T AT 91904163T AT E93138 T1 ATE93138 T1 AT E93138T1
Authority
AT
Austria
Prior art keywords
insulin sensitizing
treat hypertension
sensitizing agents
insulin
hypertension
Prior art date
Application number
AT91904163T
Other languages
English (en)
Inventor
Jerry R Colca
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23898474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE93138(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of ATE93138T1 publication Critical patent/ATE93138T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
AT91904163T 1990-02-09 1991-01-23 Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie. ATE93138T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47809090A 1990-02-09 1990-02-09
EP91904163A EP0514452B2 (de) 1990-02-09 1991-01-23 Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie
PCT/US1991/000348 WO1991012003A1 (en) 1990-02-09 1991-01-23 Use of insulin sensitizing agents to treat hypertension

Publications (1)

Publication Number Publication Date
ATE93138T1 true ATE93138T1 (de) 1993-09-15

Family

ID=23898474

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91904163T ATE93138T1 (de) 1990-02-09 1991-01-23 Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.

Country Status (12)

Country Link
EP (1) EP0514452B2 (de)
JP (1) JP3544659B2 (de)
KR (1) KR0170416B1 (de)
AT (1) ATE93138T1 (de)
AU (1) AU651571B2 (de)
CA (1) CA2071629C (de)
DE (1) DE69100282T3 (de)
DK (1) DK0514452T4 (de)
ES (1) ES2059121T5 (de)
GR (1) GR3034508T3 (de)
HK (1) HK153996A (de)
WO (1) WO1991012003A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175179A (en) * 1991-09-25 1992-12-29 Pfizer Inc. Method for treating hypertension
US5874454A (en) * 1993-09-15 1999-02-23 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
US5925656A (en) * 1995-04-10 1999-07-20 Dr. Reddy's Research Foundation Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
NZ330774A (en) * 1996-04-05 1999-06-29 Takeda Chemical Industries Ltd Pharmaceutical composition having angiotensin ii antagonistic activity or salt thereof with an insulin-sensitivity increasing compound and postprandial hyperglycemia in diabetes mellitus and antagonistic activity and increased insulin-sensitivity
US5958957A (en) * 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
AU2381397A (en) * 1996-04-19 1997-11-12 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
US5919782A (en) * 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5801173A (en) * 1996-05-06 1998-09-01 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
ZA973848B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them.
ZA973850B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel antidiabetic compounds having hypolipidaemic, anti-hypertensive properties, process for their preparation and pharmaceutical compositions containing them.
CA2257284C (en) * 1996-05-31 2005-10-04 Sankyo Company Limited Remedy for autoimmune diseases
NZ333065A (en) * 1996-05-31 2000-05-26 Sankyo Co Treatment or prevention of autoimmune diseases using an insulin resistance improving thiazolidinedione derivative
US6114526A (en) * 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
AU744518B2 (en) 1996-07-01 2002-02-28 Dr. Reddy's Laboratories Limited Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6372750B2 (en) 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
US5885997A (en) * 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
USRE39266E1 (en) * 1996-07-01 2006-09-05 Dr. Reddy's Laboratories, Limited Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6313113B1 (en) 1997-04-15 2001-11-06 Reddy-Cheminor, Inc. Heterocyclic compounds having antidiabetic, hypolipidemic and antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US6011031A (en) * 1997-05-30 2000-01-04 Dr. Reddy's Research Foundation Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them
AU9762798A (en) * 1997-11-12 1999-05-31 Kyoto Pharmaceutical Industries, Ltd. Novel thiazolidine compounds and medicinal utilization thereof
HK1041201A1 (zh) * 1998-11-11 2002-07-05 Smithkline Beecham Plc 貝塔激動劑和抗糖尿病製劑的配伍
PE20010580A1 (es) * 1999-09-03 2001-05-25 Takeda Chemical Industries Ltd Composicion farmaceutica para tratar la diabetes
EP2638898A1 (de) 2012-03-16 2013-09-18 Sanovel Ilac Sanayi ve Ticaret A.S. Metformin- und Pioglitazonformulierung mit verschiedenen Freisetzungsprofilen
EP3025707A1 (de) 2014-11-27 2016-06-01 Arven Ilac Sanayi Ve Ticaret A.S. Mehrschichtige tablette mit metformin und pioglitazon
TR201620309A2 (tr) 2016-12-30 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Metformi̇n hi̇droklori̇t ve pi̇ogli̇tazon hi̇droklori̇ti̇n farmasöti̇k bi̇leşi̇mleri̇

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3542927A (en) * 1965-08-10 1970-11-24 Pfizer Reduction of blood sugar levels with aminomethylindoles
DE2965655D1 (en) * 1978-06-28 1983-07-21 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
JPS5522636A (en) † 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
DE3169094D1 (en) * 1980-11-20 1985-03-28 Beecham Group Plc Secondary amines
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
EP0142102B1 (de) † 1983-11-04 1987-09-23 Beecham Group Plc Tertiäre Amine
US4602044A (en) † 1983-12-19 1986-07-22 Eli Lilly And Company β-phenethanolamine antiobesity agents
DE3419935A1 (de) * 1984-05-28 1985-11-28 Merck Patent Gmbh, 6100 Darmstadt Verwendung von hydroxyindolderivaten bei der senkung des blutdrucks
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
GB8607312D0 (en) † 1986-03-25 1986-04-30 Ici Plc Therapeutic agents
FR2611500B1 (fr) * 1987-03-06 1990-05-04 Lipha Emploi de derives du biguanide dans la preparation de medicaments
IE940525L (en) * 1988-05-25 1989-11-25 Warner Lambert Co Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents
GB8820389D0 (en) * 1988-08-26 1988-09-28 Beecham Group Plc Novel compounds
US5143930A (en) * 1990-02-07 1992-09-01 Sankyo Company, Limited Thiazolidine derivatives with anti-diabetic activity, their preparation and their use

Also Published As

Publication number Publication date
EP0514452B1 (de) 1993-08-18
ES2059121T3 (es) 1994-11-01
DK0514452T3 (da) 1993-11-29
DK0514452T4 (da) 2000-09-18
CA2071629C (en) 1997-12-30
JPH05506430A (ja) 1993-09-22
AU651571B2 (en) 1994-07-28
DE69100282T3 (de) 2001-01-11
EP0514452A1 (de) 1992-11-25
WO1991012003A1 (en) 1991-08-22
CA2071629A1 (en) 1991-08-10
EP0514452B2 (de) 2000-07-19
HK153996A (en) 1996-08-16
ES2059121T5 (es) 2000-12-01
GR3034508T3 (en) 2000-12-29
DE69100282T2 (de) 1994-01-05
KR0170416B1 (ko) 1999-02-18
AU7241691A (en) 1991-09-03
DE69100282D1 (de) 1993-09-23
JP3544659B2 (ja) 2004-07-21

Similar Documents

Publication Publication Date Title
DE69100282D1 (de) Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
DE69424537D1 (de) Therapeutischer wirkstoff zur behandlung von melanomen
ATE233738T1 (de) Kleine moleküle anwendbar in der behandlung von entzündgskrankheiten
EA200100572A1 (ru) Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
DE69535264D1 (de) Verfahren zur behandlung von diabetes mittels kgf
ATE218350T1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
DE69617729D1 (de) Verwendung von antimineralcorticoidverbindungen gegen das drogenentzugssyndrom
DE69721824D1 (de) Verwendung von carbonanhydrase-hemmern zur behandlung von makulär-ödemen
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
FI951024A0 (fi) Typpi-substituoidut akridiinit ja sytokromi P450-inhibiittorit ja käyttömenetelmät
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
ATE293972T1 (de) Behandlung von chronischen schmerzen
ATE252387T1 (de) Verwendung von staurosporine derivaten zur behandlung von okularen neovaskularen erkrankungen
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
DE69124382D1 (de) Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine
DE69830811D1 (de) Verwendung von Oxazolidinonderivaten zur Behandlung von Psoriasis
ATE200865T1 (de) Verwendung von phosphorderivaten von alkaloiden zur behandlung von endokrinopathien

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee